<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Laussmann MA</submitter><funding>Science Foundation Ireland</funding><funding>Health Research Board</funding><pagination>1584-97</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3130899</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(10)</volume><pubmed_abstract>Antiapoptotic Bcl-2 family proteins are often highly expressed in chemotherapy-resistant cancers and impair mitochondrial outer membrane permeabilisation (MOMP), an important requirement for caspase activation via the intrinsic apoptosis pathway. Interestingly, although Bcl-2 overexpression in HeLa cervical cancer cells abrogated caspase processing in response to intrinsic apoptosis induction by staurosporine, tunicamycin or etoposide, residual caspase processing was observed following proteasome inhibition by bortezomib ([(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid), epoxomicin (N-acetyl-N-methyl-lisoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide) or MG-132 (N-(benzyloxycarbonyl)leucinylleucinylleucinal). Similar responses were found in Bcl-2-overexpressing H460 NSCLC cells and Bax/Bak-deficient mouse embyronic fibroblasts. Mild caspase processing resulted in low DEVDase activities, which were MOMP independent and persisted for long periods without evoking immediate cell death. Surprisingly, depletion of caspase-3 and experiments in caspase-7-depleted MCF-7-Bcl-2 cells indicated that the DEVDase activity did not originate from effector caspases. Instead, Fas-associated death domain (FADD)-dependent caspase-8 activation was the major contributor to the slow, incomplete substrate cleavage. Caspase-8 activation was independent of death ligands, but required the induction of autophagy and the presence of Atg5. Depletion of XIAP or addition of XIAP-antagonising peptides resulted in a switch towards efficient apoptosis execution, suggesting that the requirement for MOMP was bypassed by activating the caspase-8/caspase-3 axis. Combination treatments of proteasome inhibitors and XIAP antagonists therefore represent a promising strategy to eliminate highly resistant cancer cells, which overexpress antiapoptotic Bcl-2 family members.</pubmed_abstract><journal>Cell death and differentiation</journal><pubmed_title>Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.</pubmed_title><pmcid>PMC3130899</pmcid><funding_grant_id>RP/2008/7</funding_grant_id><funding_grant_id>09/RFP/BIC2375</funding_grant_id><funding_grant_id>RP/2006/258</funding_grant_id><pubmed_authors>Wurstle ML</pubmed_authors><pubmed_authors>Delgado ME</pubmed_authors><pubmed_authors>Laussmann MA</pubmed_authors><pubmed_authors>Rehm M</pubmed_authors><pubmed_authors>Dussmann H</pubmed_authors><pubmed_authors>Passante E</pubmed_authors><pubmed_authors>Devocelle M</pubmed_authors><pubmed_authors>Prehn JH</pubmed_authors><pubmed_authors>Rauen JA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.</name><description>Antiapoptotic Bcl-2 family proteins are often highly expressed in chemotherapy-resistant cancers and impair mitochondrial outer membrane permeabilisation (MOMP), an important requirement for caspase activation via the intrinsic apoptosis pathway. Interestingly, although Bcl-2 overexpression in HeLa cervical cancer cells abrogated caspase processing in response to intrinsic apoptosis induction by staurosporine, tunicamycin or etoposide, residual caspase processing was observed following proteasome inhibition by bortezomib ([(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid), epoxomicin (N-acetyl-N-methyl-lisoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]-L-threoninamide) or MG-132 (N-(benzyloxycarbonyl)leucinylleucinylleucinal). Similar responses were found in Bcl-2-overexpressing H460 NSCLC cells and Bax/Bak-deficient mouse embyronic fibroblasts. Mild caspase processing resulted in low DEVDase activities, which were MOMP independent and persisted for long periods without evoking immediate cell death. Surprisingly, depletion of caspase-3 and experiments in caspase-7-depleted MCF-7-Bcl-2 cells indicated that the DEVDase activity did not originate from effector caspases. Instead, Fas-associated death domain (FADD)-dependent caspase-8 activation was the major contributor to the slow, incomplete substrate cleavage. Caspase-8 activation was independent of death ligands, but required the induction of autophagy and the presence of Atg5. Depletion of XIAP or addition of XIAP-antagonising peptides resulted in a switch towards efficient apoptosis execution, suggesting that the requirement for MOMP was bypassed by activating the caspase-8/caspase-3 axis. Combination treatments of proteasome inhibitors and XIAP antagonists therefore represent a promising strategy to eliminate highly resistant cancer cells, which overexpress antiapoptotic Bcl-2 family members.</description><dates><release>2011-01-01T00:00:00Z</release><publication>2011 Oct</publication><modification>2024-11-09T04:08:09.205Z</modification><creation>2019-03-27T03:06:45Z</creation></dates><accession>S-EPMC3130899</accession><cross_references><pubmed>21455219</pubmed><doi>10.1038/cdd.2011.27</doi></cross_references></HashMap>